Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method

Diagnostic Microbiology and Infectious Disease

Volumn 48, Issue 3, 2004, Pages 207-210

  Ngan, Cecilia C L ^a   Lim, Tongying ^b   Choo, Chin Mun ^b   Toh, Grace L X ^b   Lim, Yok Seng ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b SINGAPORE POLYTECHNIC   (Singapore)

Author keywords

Etest; Mycoplasma hominis; Resistance; Singapore; Susceptibility

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLINDAMYCIN; GATIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG POTENCY; GEOGRAPHIC ORIGIN; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA HOMINIS; NONHUMAN; PRIORITY JOURNAL; SINGAPORE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; AZITHROMYCIN; CIPROFLOXACIN; CLINDAMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA HOMINIS; QUINOLINES; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SINGAPORE; TETRACYCLINE;

EID: 1542404788     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2003.10.004     Document Type: Article

References (16)

1. Bébéar C.M., Renaudin H., Charron A., Bové J.M., Bébéar C., Renaudin J. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother. 42:1998;2304-2311.
2. Bébéar C.M., Renaudin J., Charron A., Renaudin H., de Barbeyrac B., Schaeverbeke T., Bébéar C. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis. Antimicrob Agents Chemother. 43:1999;954-956.
3. Dósa E., Nagy E., Falk W., Szoõke I., Ballies U. Evaluation of the Etest for susceptibility testing of Mycoplasma hominis and Ureaplasma urealyticum. J Antimicrob Chemother. 43:1999;575-578.
4. Duffy L.B., Crabb D., Searcey K., Kempf M.C. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. J Antimicrob Chemother. 45:(Suppl S1):2000;29-33.
5. Kenny G.E., Cartwright F.D. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinopristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother. 45:2001;2604-2608.
6. Koutsky L.A., Stamm W.E., Brunham R.C., Stevens C.E., Cole B., Hale J., Davick P., Holmes K.K. Persistence of Mycoplasma hominis after therapy Importance of tetracycline resistance and of coexisting vaginal flora. Sex Transm Dis. 28:1983;141-143.
7. Meyer R.D., Clough W. Extragenital Mycoplasma hominis infections in adults emphasis on immunosuppression. Clin Infect Dis. 17:(Suppl 1):1993;243-249.
8. Mattila P.S., Carlson P., Sivonen A., Savola J., Luosto R., Salo J., Valtonen M. Life-threatening Mycoplasma hominis mediastinitis. Clin Infect Dis. 29:1999;1529-1537.
9. Pereyre S., Gonzalez P., De Barbeyrac B., Darnige A., Renaudin H., Charron A., Raherison S., Bébéar C., Bébéar C.M. Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentens and for acquired resistance to macrolides in M. hominis. Antimicrob Agents Chemother. 46:2002;3142-3150.
10. Samra Z., Rosenberg S., Soffer Y. In vitro susceptibility of Mycoplasma hominis clinical isolated to tetracyclines, quinolones and macrolides. Diagn Microbiol Infect Dis. 44:2002;359-361.
11. Taylor-Robinson D., McCormack W.M. Medical progress The genital mycoplasmas. N Engl J Med. 302:1980;1003-1063.
12. Ullmann U., Schubert S., Krausse R. Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis. J Antimicrob Chemother. 43: (Suppl C):1999;33-36.
13. Waites, K. B., Rudd P. T., Crouse D. T., Canupp K. C., Nelson K. G., Ramsey C., & H. Cassell G. (1988). Chronic Ureaplama urealyticum and Mycoplasma hominis infections of central nervous system in preterm infants. Lancet I, 17-21
14. Waites K.B., Crabb D.M., Duffy L.B., Cassell G.H. Evaluation of the Etest for detection of tetracycline resistance in Mycoplasma hominis. Diagn Microbiol Infect Dis. 27:1997;117-122.
15. Waites K.B., Canupp K.C., Kenny G.E. In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones determined by Etest. Antimicrob Agents Chemother. 43:1999;2571-2573.
16. Waites K. B., Bébéar C. M., Robertson J. A., Talkington D. F., Kenny G. E. (2001). Cumitech 34, Laboratory diagnosis of mycoplasmal infections. F. S. Nolte (Coordinating ed), American Society for Microbiology, Washington, D. C